Diagnostic Center | April 15, 2024
Teva confirms efficacy and safety of Ajovy for prevention of migraine
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
Elegen is the only DNA manufacturer delivering the unique combination of complexity, length and NGS-verified accuracy within days
PLI scheme envisages manufacturing of 41 Bulk Drugs with a total outlay of Rs. 6,940 cr. during the tenure of the scheme from 2020-21 to 2029-30
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS)
In fact, the overall CPHI Pharma Index – a collateralised metric of all major ranking categories – has risen by more than 8%, the largest year-on-year gain in the survey’s six year history
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
The estimated capex is to the tune of Rs. 140 crore to be funded through debt and internal accrual
‘Infinite Care’ comprises two key pillars - Sparsh Sankalpa and Sparsh Sukshema
Subscribe To Our Newsletter & Stay Updated
